Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Obstet Gynecol ; 95(2): 278-83, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10674594

RESUMO

OBJECTIVE: To assess whether estrogen treatment given to postmenopausal women without vasomotor symptoms improves balance more than placebo. METHODS: Forty healthy postmenopausal women without vasomotor symptoms were randomized to transdermal 17beta-estradiol (E2) 50 microg/day for 14 weeks or identical transdermal placebo patches. Postural balance was measured with dynamic posturography before and after 4, 12, and 14 weeks of therapy. In this test, the visual, vestibular, and somatosensory systems were provoked with increasing difficulty and body sway was measured with a dual forceplate. A low score showed large sway and a score of 100 showed no sway at all. RESULTS: Thirty-eight women completed the study. Both groups had normal balance for their ages and near maximum scores in the three easier balance tests at baseline. In the most difficult test, both groups improved their postural balance significantly (from 13 to 32 and from 22 to 39, respectively) after 4 weeks. Thereafter, no change was seen. One problem was low statistical power, but the relative change in balance did not differ between groups. The comparison did not show even a minute advantage of E2 over placebo, so a study with higher power would probably not have shown a more pronounced effect of estrogen than placebo. The change over time did not differ between groups, which indicates a significant learning effect. CONCLUSION: In women without vasomotor symptoms, estrogen therapy did not seem to increase postural balance significantly more than placebo. However, we could not rule out that estrogens affect postural balance in women with vasomotor symptoms.


Assuntos
Estradiol/farmacologia , Pós-Menopausa/fisiologia , Equilíbrio Postural/efeitos dos fármacos , Administração Cutânea , Estradiol/administração & dosagem , Feminino , Fogachos , Humanos , Pessoa de Meia-Idade , Pós-Menopausa/efeitos dos fármacos , Valores de Referência , Índice de Gravidade de Doença
2.
Maturitas ; 31(2): 117-22, 1999 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-10227004

RESUMO

BACKGROUND: Most but not all women suffer from vasomotor symptoms around menopause. The exact mechanisms behind these symptoms are unknown, but the rate of decline in estrogen concentrations has been suggested to affect the risk of hot flushes. OBJECTIVE: The objective was to assess whether vasomotor symptoms were induced in women without previous such symptoms, when the women were given combined estradiol and progestagen therapy for 3 months, whereafter therapy was abruptly withdrawn. MATERIALS AND METHOD: After randomization, 40 postmenopausal women without previous or current vasomotor symptoms were treated transdermally with either 50 micrograms/day 17 beta-estradiol or placebo during 14 weeks. During the 13th and 14th weeks, treatment was combined with oral medroxyprogesterone acetate 10 mg/day. Serum estradiol and follicle-stimulating hormone (FSH) concentrations were analysed before and after 12 weeks of therapy. Climacteric symptoms were assessed at the same intervals as well as 8 weeks after the end of therapy. RESULTS: All women had low pretreatment levels of estradiol and high FSH concentrations. During estradiol therapy estradiol levels increased significantly, whereas FSH only decreased slightly. No woman developed vasomotor symptoms after withdrawal of therapy. CONCLUSION: Postmenopausal women without previous or current vasomotor symptoms did not develop such symptoms when estrogen replacement therapy was first instituted and then abruptly stopped. Probably other factors than the rate with which estrogen concentrations decrease determine whether or not a woman will develop vasomotor symptoms. Evidently, estrogens can be prescribed to a woman who has no vasomotor symptoms, without much risk of inducing such symptoms if she decides to abandon therapy, even after 3 months of treatment.


Assuntos
Estradiol/farmacologia , Terapia de Reposição de Estrogênios , Fogachos/metabolismo , Pós-Menopausa , Administração Cutânea , Método Duplo-Cego , Estradiol/administração & dosagem , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Humanos , Acetato de Medroxiprogesterona , Indutores da Menstruação , Pessoa de Meia-Idade
3.
Scand J Plast Reconstr Surg Hand Surg ; 30(4): 267-73, 1996 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8976021

RESUMO

The repair and contraction during connective tissue repair of mesenteric perforations is prolonged in mice compared with rats. In the present study the stimulating effect of transforming growth factor beta 1 (TGF-beta 1) on different aspects of such repair of the mouse mesentery was assessed. The number of closed mesenteric perforations were counted on different days after operation and the free peritoneal cells were counted, the mitotic index was assessed, and actin distribution of fibroblasts around the perforation was studied with laser scanning confocal microscopy. TGF-beta 1 significantly increased the speed of closure and seemed to induce more actin in fibroblasts at the wound margin. It did not significantly influence the mitotic index, but fewer free peritoneal cells were obtained in mice treated with TGF-beta 1. We conclude that TGF-beta 1 is a potent stimulator of connective tissue repair and contraction in mice. The different methods of closure in rats and mice implicate different molecular responses in wounds and further studies on the stimulating effect of TGF-beta 1 may indicate basic fibroblastic cellular mechanisms that are active during contraction in connective tissue repair.


Assuntos
Tecido Conjuntivo/fisiologia , Mesentério/patologia , Fator de Crescimento Transformador beta/fisiologia , Cicatrização/fisiologia , Animais , Masculino , Camundongos , Camundongos Endogâmicos , Índice Mitótico
4.
J Biomed Mater Res ; 32(3): 439-46, 1996 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8897150

RESUMO

Since the 1950s a number of implantable substances have been used to study granulation tissue formation: steel mesh, polyvinylalcohol (PVA), polytetrafluoroethylene (PTFE), polyurethane, and viscose cellulose sponges (VCS). The side effects of these materials on granulation tissue formation vary considerably. An ideal material does not interfere with the normal wound-healing process and collects as many cells as possible for further analysis. Viscose cellulose sponge has been shown to be one of the most inert materials for this purpose. In this study we examined the correlation between changes in the structure of the sponge and the number of cells harvested and the synthesis of granulation tissue after subcutaneous implantation in rats. It was discovered that it is possible to control the structure of the sponge and by certain changes in this structure increase the number of invading cells and the production of granulation tissue in the sponge. There is, however, a distinct plateau after which changes in structure do not increase the number of invading cells and the production of granulation tissue in the sponge.


Assuntos
Celulose/toxicidade , Reação a Corpo Estranho/etiologia , Tecido de Granulação/patologia , Próteses e Implantes/efeitos adversos , Tampões de Gaze Cirúrgicos/efeitos adversos , Animais , Reação a Corpo Estranho/patologia , Masculino , Ratos , Ratos Sprague-Dawley
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...